Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model.
Poloxamer 188 has been reported to inhibit thrombosis, decrease whole blood viscosity, and improve perfusion of damaged tissue. Mannitol has free radical scavenging capabilities that might contribute to myocardial salvage after ischemia. Because these agents appear to work in different ways, we studied their cardioprotective properties when they were used separately and in combination. After 75 minutes of left anterior descending coronary artery (LAD) occlusion, dogs received poloxamer 188 (48 mg/kg), mannitol (0.5 gm/kg), or both intravenously during an additional 15 minutes of LAD occlusion and for 45 minutes of reperfusion, whereas control dogs received an equal volume of saline solution. After surgery the animals were maintained for 24 hours and then killed. Areas of myocardial infarction (MI) and risk of infarction (R) were calculated by means of planimetric analysis of slices of myocardium stained with 1.5% triphenyltetrazolium and 0.5% Evans blue dye. The ratio of MI/R (mean +/- standard error of the mean) were: control, 25.6 +/- 1.8% (n = 10); poloxamer 188, 12.7 +/- 2.0% (n = 10); mannitol, 10.6 +/- 2.5% (n = 11); and poloxamer 188 plus mannitol, 8.0 +/- 4.1% (n = 10). Measurement of microvascular blood flow indicated a similar 86% to 91% reduction of blood flow to the area at risk in all treatment groups. Consequently both poloxamer 188 and mannitol appear to increase salvage of ischemic myocardium and a combination of the two may be more effective than either agent alone.
Justicz
A G
AG
Veterans Affairs Medical Center, Decatur, GA 30033.
Farnsworth
W V
WV
Soberman
M S
MS
Tuvlin
M B
MB
Bonner
G D
GD
Hunter
R L
RL
Martino-Saltzman
D
D
Sink
J D
JD
Austin
G E
GE
D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects; D004285:Dogs; D004359:Drug Therapy, Combination; D008353:Mannitol / Q000008:administration & dosage / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000473:pathology; D011060:Poloxalene / Q000008:administration & dosage / Q000627:therapeutic use*
D008353:Mannitol; D011060:Poloxalene